DGAP-News

Oxford Immunotec receives 2014 Queen's Award for Enterprise

DGAP-News: Oxford Immunotec /
Oxford Immunotec receives 2014 Queen's Award for Enterprise

21.04.2014 / 11:00

---------------------------------------------------------------------

OXFORD, United Kingdom and MARLBOROUGH, Mass., 2014-04-21 11:00 CEST (GLOBE
NEWSWIRE) --
Oxford Immunotec Global PLC (Nasdaq:OXFD) today announced that it has received
a Queen's Award for Enterprise - the UK's highest accolade in business success.

The Queen's Awards are designed to recognise and encourage the achievements by
businesses in the UK in the fields of Innovation, International Trade and
Sustainable Development. The awards are made annually by Her Majesty The Queen
and are only given for the highest levels of excellence demonstrated in each
category.

Oxford Immunotec received a prestigious Queen's Award for International Trade
for Continuous Achievement, based on its substantial overseas revenue growth
and commercial success over six years. From 2007 to 2012, Oxford Immunotec grew
its overseas earnings by greater than 1300% through expansion into markets
worldwide including the United States, Japan and China. The Company's
T-SPOT(r).TB test for tuberculosis is now approved for sale in over 50 countries
on five continents. The T-SPOT.TB test helps to diagnose tuberculosis infection
before it has progressed to full-blown disease, allowing treatment of carriers
to prevent further spread of TB infection and disease.

Commenting on the Company's achievement, Dr Peter Wrighton-Smith, Oxford
Immunotec's Chief Executive Officer, said 'We are delighted and honoured to
have the achievements of the Company recognized by Her Majesty. We look forward
to continuing to expand the countries we serve and in continuing our strong
export-led growth.'

Notes to Editors:

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company
committed to improving patient care by providing advanced, innovative tests in
the field of immunology. The proprietary T-SPOT(r) technology platform measures
the responses of specific immune cells, known as T cells, to inform the
diagnosis, prognosis and monitoring of patients with immunologically controlled
diseases. T cells are a central component of the human body's immune system,
and are implicated in the control and progression of many medical conditions,
including certain types of infectious diseases, cancers and autoimmune
diseases. The Company's initial product developed using the T-SPOT technology
platform is the T-SPOT.TB test, which is used to test for latent tuberculosis
infection. The T-SPOT.TB test has been approved for sale in over 50 countries,